About this document

1 s20 S1521692625000659 Main - 251201 - 175115 by Jitesh Jain is a document available to read on EtoBox.

This article reviews the advancements in CAR-T cell therapy for multiple myeloma, highlighting two FDA-approved products targeting B cell maturation antigen (BCMA). These therapies have shown significant efficacy in treating advanced disease but are associated with unique toxicities and challenges related to therapeutic resistance. Ongoing research aims to enhance the effectiveness and safety of CAR-T therapies, particularly in earlier treatment lines for patients with relapsed or refractory multiple myelom

Author

Jitesh Jain

Language

EN